Key result
Mavacamten inhibits actin-myosin interaction at low calcium, potentially reducing hypercontractility in HCM.
Why the study?
Mutations in sarcomeric proteins in hypertrophic cardiomyopathy disrupt actin-myosin interaction and cause hypercontractility, prompting evaluation of the cardiac myosin inhibitor mavacamten on calcium regulation of these contractile proteins.
Does mavacamten inhibit the effect of the L352P mutation on actin-myosin interaction at low calcium concentrations in isolated cardiac contractile proteins?
Does mavacamten inhibit the effect of the L352P mutation on actin-myosin interaction at low calcium concentrations in isolated cardiac contractile proteins?
Mavacamten slows cross-bridge kinetics and inhibits actin-myosin interaction at low calcium concentrations in the presence of the L352P mutation, providing a mechanistic basis for reducing hypercontractility in hypertrophic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Supports mavacamten mechanism in L352P HCM; leaves open clinical translation.
Mutations in sarcomeric proteins associated with hypertrophic cardiomyopathy (HCM) lead to disruption of actin-myosin interaction, its calcium regulation, and myocardial hypercontractility. About half of such mutations are found in the MYBPC3 gene encoding cardiac myosin binding protein C (cMyBP-C). A new approach to normalize cardiac contractile function in HCM is the use of inhibitors of β-cardiac myosin function, one of which is mavacamten. We studied the effect of mavacamten on calcium regulation of actin-myosin interaction using isolated cardiac contractile proteins in an in vitro motility assay. The L352P mutation did not affect the maximum sliding velocity of regulated thin filaments on myosin in an in vitro motility assay and the calcium sensitivity of the velocity and led to underinhibition of actin-myosin interaction at low calcium concentrations. Mavacamten decreased the maximum sliding velocity of thin filaments with WT and L352P C0-C2 fragments, and in the presence of L352P C0-C2 fragment stopped their movement at low calcium concentrations. Slowing down the kinetics of cross-bridge and inhibition of actin-myosin interaction at low calcium concentrations in the presence of mavacamten may reduce hypercontractility in HCM and the degree of myocardial hypertrophy.
No takes yet. Share an insight, caveat, or question.
A. M. Kochurova (2025) studied this question. Mavacamten inhibited actin-myosin interaction at low calcium levels in the presence of L352P mutated cMyBP-C, potentially reducing hypercontractility in HCM.
Synapse has enriched 10 related papers. Consider them for comparative context: